A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT02013830
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab [Avastin] — DRUG
    7.5mg/kg iv on day 1 of each 3 week cycle.
  • capecitabine [Xeloda] — DRUG
    1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.

Study Details

This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.

Key Dates

First listed
Dec 17, 2013
Start date
May 31, 2005
Status verified
May 2014
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008

Study Design

Enrollment
45 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Avastin + Xeloda

Primary Outcome Measure

Percentage of Participants With Objective Response (OR) [ Time Frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up ]

Related Studies